Lexeo’s Approach To Gene Therapy For Common Conditions
CEO Expects First Commercial Launch As Early As 2026
Executive Summary
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.
You may also be interested in...
Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.